Northwest Biotherapeutics Inc.
7600 Wisconsin Avenue
Suite 750
Bethesda,
MD 20814
United States - Map
Phone: 240-497-9024
Web Site: http://www.nwbio.com
| Northwest Biotherapeutics, Inc., a development stage biotechnology company, engages in the discovery, development, and commercialization of immunotherapy products that generate and enhance immune system responses to treat cancer. Its technology platforms include dendritic cell-based cancer vaccines (DCVax) and monoclonal antibodies for cancer therapeutics. The companys primary products include DCVax-Prostate for the treatment of non-metastatic hormone independent prostate cancer, which cleared Phase III clinical trial; DCVax-Brain, which is in Phase II clinical trial, for the treatment of Glioblastoma multiforme; and DCVax-LB, which cleared Phase I clinical trial for the treatment of non-small cell lung cancer. It also develops DCVax-Direct that cleared Phase I clinical trial for the treatment of ovarian, head, and neck cancer; and DCVax-L, a Phase I/II clinical trial product for the treatment of respectable solid tumors. In addition, Northwest develops CXCR4 antibodies, which involves in various phases of disease progression, including proliferation of the primary tumor, migration of cancer cells out of the primary tumor, and establishment of distant metastatic sites for the treatment of non-small cell lung cancer, breast cancer, GBM, colon cancer, melanoma, prostate, pancreatic, kidney, ovarian, and certain blood cancers. The company was founded in 1996 and is headquartered in Bethesda, Maryland. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Alton L. Boynton Ph.D., 64
Co-Founder, Chief Exec. Officer, Pres, Chief Operating Officer, Chief Scientific Officer, Sec. |
N/A
| N/A | Dr. Marnix L. Bosch Ph.D., MBA, 49
Chief Technical Officer and VP of Vaccine R&D |
N/A
| N/A | Mr. Anthony P. Deasey , 59
Consultant |
$
215.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.20% Nasdaq 
Profile
